Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Lead Drug BTM-3566 at the 2022 AACR Annual Meeting
RESEARCH TRIANGLE PARK, North Carolina, April 8, 2022 /PRNewswire/ — Bantam Pharmaceutical, a drug discovery and development company targeting the selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 to be held on 8and-13and April in New Orleans. Data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control pathway to induce apoptosis in cell lines, xenografts, and patient-derived xenograft (PDX) models of diffuse large B-cell lymphoma (DLBCL ).
The poster presentation on Wednesday April 13and demonstrates the robust in vivo activity of BTM-3566, including complete and durable regressions in 6 out of 9 PDX models with a 100% response rate across a range of difficult-to-treat DLBCL tumors. Equally important, BTM-3566 acts through a novel mechanism of action with activity on multiple genomic and phenotypic subtypes of DLBCL, suggesting that it represents an effective treatment option for patients progressing with reference agents. existing. Emerging data characterizing responses and dependence on mitochondrial protein expression will also be presented.
The summary is available now on the AACR website.
Michael StocumCEO of Bantam Pharmaceutical, said: “We are excited to present this new data at the AACR. Together with our academic collaborators, we continue to improve our understanding of the novel mechanism of BTM-3566 and its ability to induce apoptosis in cancer cells. We expect to file an Investigational New Drug (IND) application for BTM-3566 this quarter (Q2 2022) and are ready to initiate clinical trials later this year. Our IND and preclinical data are generating considerable excitement among oncologists as we move into the clinic.”
Title: BTM-3566 co-opts mitochondrial quality control pathways to induce apoptosis and complete tumor regression in DLBCL cell lines, xenografts and PDX models
Session title: Mitochondrial metabolism in cancer
Session start time: 04/13/2022 09:00 CDT
Location: Section 9 Poster
BTM-3566 is a novel, orally available, small-molecule compound with broad anticancer activity in hematological and solid tumors, initially focused on diffuse large B-cell lymphoma (DLBCL). The anticancer mechanism of action of BTM-3566 is unique and differentiated from other therapeutic agents, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being finalized for submission in Q2 2022.
About Bantam Pharmaceutical
Bantam Pharmaceutical is a drug discovery and development company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. With its unique expertise in mitochondrial cell biology, Bantam is developing novel, first-in-class small molecule oral therapies for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Learn more about https://bantampharma.com/.
SOURCEBantam Pharmaceutical, LLC